Athenex, Inc. (ATNX) – Recovery of Investment Losses
The White Law Group is investigating potential securities claims involving broker-dealers who may have unsuitably recommended Athenex, Inc. to investors.
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development and commercialization of novel therapies for the treatment of cancer, according to Market Watch.
According to Market Watch as of November 15, 2020, shares of ATNX are down more than -27% in the past year.
The problem with pharmaceutical and biotech investments is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy testing trials that yield specific data. If the expected data or end points are not met, that could be bad news for investors.
Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.